Aligos Therapeutics【ALGS】銘柄情報

Aligos Therapeutics Inc (ALGS) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

4.85

( -9.18% )

買値

3.72

売値

6.30

出来高

128,440

4.80 日の範囲 5.3359

4.8098 52 週間の範囲 13.6892

時価総額

30.011M

前日終値

5.34

始値

5.30

時刻

5.13

最終取引時間

財務取引量

US$ 639,295

VWAP

4.9774

平均取引量 (3 か月)

US$ 177,359

発行済株式数

6,187,807

配当利回り

PER

-0.74

1 株当たり利益 (EPS)

-2.78

歳入

4.71M

純利益

-90.32M

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment ... Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.aligos.com

本社

South San Francisco, United States

設立

2026

Aligos Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ALGS. The last closing price for Aligos Therapeutics was US$5.34. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 4.8098 to US$ 13.6892.

Aligos Therapeutics currently has 6,187,807 shares in issue. The market capitalisation of Aligos Therapeutics is US$30.01 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.74.

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.09	-18.3501683502	5.94	5.94	4.8098	137734	5.36022459	CS
4	-1.26	-20.6219312602	6.11	6.875	4.8098	144718	5.83294787	CS
12	-2.64	-35.2469959947	7.49	8.97	4.8098	218767	6.97017714	CS
26	-5.27	-52.0750988142	10.12	13.6892	4.8098	135062	7.44443195	CS
52	-1.4	-22.4	6.25	13.6892	4.8098	111356	7.97764885	CS
156	3.65	304.166666667	1.2	46.8	0.3482	213673	7.96512132	CS
260	-24.3	-83.3619210978	29.15	46.8	0.3482	238984	6.85780641	CS